Dade Behring公司從美國Cleveland診所獲得如下授權：將髓過氧化物酶自動檢測商品化的特定半獨有權利。

根據Cleveland診所進行的研究發現：髓過氧化物酶檢測對發病時肌鈣蛋白A低水平（通常提示心肌細胞沒有死亡）的胸痛患者特別有診斷價值。在這種情況下，髓過氧化物酶水平升高與隨后發生的心臟病有聯系。因此簡單的MPO檢測有助于醫生鑒別出那些隨后可能心臟病發作的患者，從而指導他們在心臟病發作之前開始治療。

Cleveland診所的研究人員對急診室里主訴胸痛的600多位患者的初始髓過氧化物酶水平進行了研究。通過髓過氧化物酶檢測以及其它相關實驗室風險評估，研究人員把預測患者發病后30天～6個月出現心臟問題的能力，從54%提高至85％。在歐洲完成的一項較大規模的研究證實了這些結果。

Cleveland診所心血管科主任Eric J. Topol醫學博士說：“一項簡單的血液檢測就能夠幫助醫生鑒別出存在心臟損害危險的患者是令人興奮的，我們需要建立肌鈣蛋白的檢測來改變醫學發展現狀，髓過氧化物酶檢測或許是達到這個目標的途徑之一。”

Dade Behring to Develop Cardiac Marker Tests
 
Certain semi-exclusive diagnostic rights for the commercialization of automated diagnostic tests using myeloperoxidase (MPO) have been granted to Dade Behring (Deerfield, IL, USA) by The Cleveland Clinic (OH, USA).

According to research conducted at The Cleveland Clinic, MPO testing may be particularly beneficial in patients with chest pain who exhibit low initial troponin (a) levels, usually an indication that no heart muscle cells have died. In this case, the presence of an elevated MPO level has been linked to risk for subsequent cardiac events. Therefore, a simple MPO blood test has the potential to help doctors identify patients at risk of subsequent heart attack and refer them for treatment prior to the occurrence of heart damage.

Researchers at the Cleveland Clinic investigated initial MPO levels in more than 600 patients in the emergency room complaining of chest pain. By using an MPO blood test in addition to laboratory-based risk assessments, they increased their ability to identify patients who would have heart problems during the next 30 days to six months from 54% to 85%. A larger study in Europe has confirmed these results.

“The potential of a simple blood test to help identify patients at particular risk of heart damage is very exciting,” commented Eric J. Topol, M.D., chairman of The Cleveland Clinic’s department of cardiovascular medicine. “We need to build on the great success of the troponin test in changing medicine, and the MPO test may be a way to do that.”